NervGen Operating Income vs Income Before Tax Analysis

NGEN Stock  CAD 3.11  0.21  7.24%   
NervGen Pharma financial indicator trend analysis is infinitely more than just investigating NervGen Pharma Corp recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NervGen Pharma Corp is a good investment. Please check the relationship between NervGen Pharma Operating Income and its Income Before Tax accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NervGen Pharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Operating Income vs Income Before Tax

Operating Income vs Income Before Tax Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NervGen Pharma Corp Operating Income account and Income Before Tax. At this time, the significance of the direction appears to have almost identical trend.
The correlation between NervGen Pharma's Operating Income and Income Before Tax is 0.98. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of NervGen Pharma Corp, assuming nothing else is changed. The correlation between historical values of NervGen Pharma's Operating Income and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of NervGen Pharma Corp are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Operating Income i.e., NervGen Pharma's Operating Income and Income Before Tax go up and down completely randomly.

Correlation Coefficient

0.98
Relationship DirectionPositive 
Relationship StrengthVery Strong

Operating Income

Operating Income is the amount of profit realized from NervGen Pharma Corp operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of NervGen Pharma Corp is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on NervGen Pharma income statement and is an important metric when analyzing NervGen Pharma Corp profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.
Most indicators from NervGen Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NervGen Pharma Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NervGen Pharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Selling General Administrative is likely to drop to about 4.9 M in 2024. Issuance Of Capital Stock is expected to grow at the current pace this year

NervGen Pharma fundamental ratios Correlations

0.660.660.720.94-0.820.840.850.77-0.320.840.66-0.320.720.7-0.32-0.930.850.430.460.870.94-0.790.870.780.68
0.661.0-0.040.66-0.950.60.690.52-0.840.871.0-0.84-0.04-0.07-0.84-0.860.930.830.270.90.81-0.690.920.870.99
0.661.0-0.040.66-0.950.60.70.54-0.850.871.0-0.85-0.04-0.07-0.85-0.860.930.840.290.90.81-0.690.920.860.99
0.72-0.04-0.040.64-0.220.550.480.530.320.29-0.030.321.01.00.32-0.450.28-0.190.360.350.5-0.470.320.22-0.01
0.940.660.660.64-0.850.640.840.81-0.370.860.66-0.370.640.61-0.37-0.920.860.560.460.890.96-0.680.880.670.64
-0.82-0.95-0.95-0.22-0.85-0.63-0.81-0.690.76-0.92-0.950.76-0.22-0.190.760.95-0.98-0.82-0.38-0.99-0.930.79-0.99-0.83-0.93
0.840.60.60.550.64-0.630.760.62-0.20.670.61-0.20.550.54-0.2-0.730.660.260.520.650.73-0.680.670.850.67
0.850.690.70.480.84-0.810.760.97-0.440.770.71-0.440.480.44-0.44-0.80.770.610.590.810.85-0.70.820.70.69
0.770.520.540.530.81-0.690.620.97-0.320.630.54-0.320.530.5-0.32-0.670.640.550.620.710.75-0.620.70.50.5
-0.32-0.84-0.850.32-0.370.76-0.2-0.44-0.32-0.52-0.851.00.320.341.00.59-0.74-0.9-0.18-0.7-0.480.6-0.73-0.48-0.79
0.840.870.870.290.86-0.920.670.770.63-0.520.87-0.520.290.26-0.52-0.930.920.630.250.910.96-0.60.910.90.88
0.661.01.0-0.030.66-0.950.610.710.54-0.850.87-0.85-0.03-0.06-0.85-0.860.930.840.290.90.81-0.690.920.860.99
-0.32-0.84-0.850.32-0.370.76-0.2-0.44-0.321.0-0.52-0.850.320.341.00.59-0.74-0.9-0.18-0.7-0.480.6-0.73-0.48-0.79
0.72-0.04-0.041.00.64-0.220.550.480.530.320.29-0.030.321.00.32-0.450.28-0.190.360.350.5-0.470.320.22-0.01
0.7-0.07-0.071.00.61-0.190.540.440.50.340.26-0.060.341.00.34-0.430.26-0.220.330.320.47-0.450.290.2-0.03
-0.32-0.84-0.850.32-0.370.76-0.2-0.44-0.321.0-0.52-0.851.00.320.340.59-0.74-0.9-0.18-0.7-0.480.6-0.73-0.48-0.79
-0.93-0.86-0.86-0.45-0.920.95-0.73-0.8-0.670.59-0.93-0.860.59-0.45-0.430.59-0.98-0.64-0.33-0.97-0.970.8-0.97-0.85-0.86
0.850.930.930.280.86-0.980.660.770.64-0.740.920.93-0.740.280.26-0.74-0.980.760.320.990.93-0.80.990.840.92
0.430.830.84-0.190.56-0.820.260.610.55-0.90.630.84-0.9-0.19-0.22-0.9-0.640.760.480.750.62-0.550.780.490.77
0.460.270.290.360.46-0.380.520.590.62-0.180.250.29-0.180.360.33-0.18-0.330.320.480.360.42-0.440.40.260.26
0.870.90.90.350.89-0.990.650.810.71-0.70.910.9-0.70.350.32-0.7-0.970.990.750.360.95-0.841.00.80.88
0.940.810.810.50.96-0.930.730.850.75-0.480.960.81-0.480.50.47-0.48-0.970.930.620.420.95-0.740.950.840.81
-0.79-0.69-0.69-0.47-0.680.79-0.68-0.7-0.620.6-0.6-0.690.6-0.47-0.450.60.8-0.8-0.55-0.44-0.84-0.74-0.83-0.62-0.69
0.870.920.920.320.88-0.990.670.820.7-0.730.910.92-0.730.320.29-0.73-0.970.990.780.41.00.95-0.830.820.91
0.780.870.860.220.67-0.830.850.70.5-0.480.90.86-0.480.220.2-0.48-0.850.840.490.260.80.84-0.620.820.91
0.680.990.99-0.010.64-0.930.670.690.5-0.790.880.99-0.79-0.01-0.03-0.79-0.860.920.770.260.880.81-0.690.910.91
Click cells to compare fundamentals

NervGen Pharma Account Relationship Matchups

NervGen Pharma fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets6.8M6.7M17.9M23.9M13.2M11.3M
Other Current Liab172.4K583.3K725.5K8.1M11.7M12.3M
Total Current Liabilities923.9K755.1K1.1M10.2M15.1M15.9M
Total Stockholder Equity5.8M5.9M16.8M13.5M(2.0M)(1.9M)
Net Tangible Assets5.3M5.4M16.3M13.0M15.0M7.7M
Retained Earnings(11.1M)(22.3M)(35.0M)(55.8M)(78.2M)(74.2M)
Accounts Payable751.6K171.8K352.5K2.0M550.4K672.0K
Cash4.1M5.6M16.9M22.5M11.7M9.9M
Non Current Assets Total509.6K473.4K475.8K726.7K720.5K555.8K
Common Stock Shares Outstanding25.9M32.1M39.3M52.6M59.6M41.5M
Liabilities And Stockholders Equity6.8M6.7M17.9M23.9M27.5M28.8M
Total Liab923.9K755.1K1.1M10.4M15.2M16.0M
Net Invested Capital5.8M5.9M16.8M13.5M(2.0M)(1.9M)
Total Current Assets6.3M6.2M17.4M23.1M12.5M10.7M
Net Working Capital5.3M5.4M16.3M12.9M(2.6M)(2.5M)
Net Debt(4.1M)(5.6M)(16.9M)(22.2M)(20.0M)(19.0M)
Cash And Short Term Investments4.1M5.6M16.9M22.5M25.8M27.1M
Net Receivables122.5K62.6K64.0K27.0K250.2K262.7K
Other Current Assets2.0M540.8K427.6K669.9K602.9K594.4K
Other Stockholder Equity1.7M5.3M9.5M11.8M13.6M14.3M
Accumulated Other Comprehensive Income1.7M5.3M9.5M11.8M13.6M14.3M
Capital Stock15.3M22.9M42.4M57.4M58.9M36.8M
Intangible Assets509.6K471.4K473.2K431.4K520.8K393.9K
Common Stock15.3M22.9M42.4M57.4M66.0M69.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for NervGen Stock Analysis

When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.